EUVIMEDEUVIMED entdecken
Crossref

A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia

Işık Odaman Al iD, Nihal Özdemir, Gizem Zengin Ersoy, Cengiz Bayram, Özgül Vupa Çilengiroğlu iD, Esra Arslantaş, Ezgi Paslı Uysalol, Ali Ayçiçek

Journal of Oncology Pharmacy Practice · 2023

DOI: 10.1177/10781552231164503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2023. Verfasst von Işık Odaman Al und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, İstanbul Medipol University Medical Faculty, İstanbul, Turkey. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Hypersensitivity, Drug Hypersensitivity. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Asparaginase is an indispensable drug in treating childhood acute lymphoblastic leukemia (ALL). Hypersensitivity reactions (HSR) are the most common side effects and interfere with the antineoplastic activity of the drug. This study aims to compare the intramuscular (IM) and intravenous (IV) administration routes of Native Escherichia coli Lasparaginase (L-ASNase) in terms of hypersensitive reactions.

Methods

L-ASNase was randomly administered IV or IM to newly diagnosed ALL patients and HSR was monitored in all patients for 1 h following the end of the IV infusion and for 2 h following the end of the IM administration of L-ASNase. Based on a retrospective review of clinical charts, reactions were identified. In order to determine the severity of each allergic reaction, we used the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for allergic reactions.

Results

A total of 1032 doses of L-ASNase were administered to 85 patients (42 males and 43 females) during the study period. Among 85 patients, 30 reactions were recorded, which means that 35% of the patients reacted. According to the CTCAE, twenty-nine out of 30 reactions (97%) were grade 2, while one (3%) was grade 4. In terms of individual doses, there was a non-significant trend toward increased incidence of reactions with IV administration (3.8% versus 0.9%, p = 0.064). The rate of reactions was higher in patients who received all IV doses ( n: 60) as compared to those who received all IM doses ( n: 25) (31.7% vs. 3.5%; chi-square= 8.415, p value=0.04). Based on the risk groups and HSR incidence, it was found that high risk group (HRG) patients were significantly more likely to develop HSR compared to the standart risk group (SRG) and intermediate risk group (MRG) patients (chi-square p = 0.003, CI: 95%; odds ratio: 3.12 and 5.91, respectively).

Conclusions

In conclusion, IM administration of L-ASNase causes significantly less HSR to L-ASNase than the IV route. Patients with HRGALL have a higher risk of HSR. Since L-ASNase is still used in many developing countries and there are problems in the supply of Erwinia chrysanthemi ASNase (Erwinia), LASNase can be administered IM to reduce the frequency of HSR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsHypersensitivityDrug HypersensitivityMaleFemaleChildHumansAsparaginaseEscherichia coliPolyethylene Glycols

Stichwörter der Autor:innen

asparaginasechildrenhypersensitivityintramuscular applicationleukemia

Substanzen

AsparaginaseAntineoplastic AgentsPolyethylene Glycols

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, İstanbul Medipol University Medical Faculty, İstanbul, Turkey.
  • Department of Pediatric Hematology and Oncology, İstinye University Medical Faculty, İstanbul, Turkey.
  • Department of Pediatric Hematology and Oncology, Altınbaş University Medical Faculty, İstanbul, Turkey.
  • Department of Pediatric Hematology and Oncology, Çam and Sakura City Hospital, İstanbul, Turkey.
  • Faculty of Sciences, Department of Statistics, Dokuz Eylul University, Izmir, Turkey.

ORCID-Profile: Işık Odaman Al, Özgül Vupa Çilengiroğlu

Zitieren

APA

Odaman Al, I., Özdemir, N., Zengin Ersoy, G., Bayram, C., Vupa Çilengiroğlu, Ö., Arslantaş, E., Paslı Uysalol, E., & Ayçiçek, A. (2023). A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552231164503

Vancouver

Odaman Al I, Özdemir N, Zengin Ersoy G, Bayram C, Vupa Çilengiroğlu Ö, Arslantaş E, et al. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia. Journal of Oncology Pharmacy Practice. 2023. doi:10.1177/10781552231164503

BibTeX
@article{OdamanAl2023,
  author = {Odaman Al, Işık and Özdemir, Nihal and Zengin Ersoy, Gizem and Bayram, Cengiz and Vupa Çilengiroğlu, Özgül and Arslantaş, Esra and Paslı Uysalol, Ezgi and Ayçiçek, Ali},
  title = {A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2023},
  doi = {10.1177/10781552231164503}
}
Kostenlos starten →